Board of Directors

Board of Directors

Mr. Pauls has served as Savara’s Chief Executive Officer since December 2020, Chair of the Board of Directors since September 2020, and the Company’s Interim Chief Executive Officer from September 2020 to December 2020. He has been a member of Savara’s Board of Directors since April 2017 and was a member of Mast Therapeutics’ Board of Directors from October 2015 to April 2017. Previously, Mr. Pauls was the founder of Spartan Biopharma Insights, LLC, where he provided strategic advisement to institutional investors, C-suite executives, board directors, et al on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization. He also previously served on the Board of Directors of Zyla Life Sciences, which merged with Assertio Therapeutics in 2020. From August 2014 to November 2019, Mr. Pauls was President, Chief Executive Officer and (from October 2015 – November 2019) a member of the Board of Directors of Strongbridge Biopharma plc, a publicly traded biopharmaceutical company that he took public onto NASDAQ via IPO in October 2015. Strongbridge is focused on therapies that target rare diseases. From April 2013 to August 2014, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded global biopharmaceutical company focused on rare diseases. Prior to Insmed, he worked at Shire Pharmaceuticals, a global specialty biopharmaceutical company, from 2007 to 2013, most recently as Senior Vice President, Head of Global Commercial Operations. Earlier in his career, Mr. Pauls held senior commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.
Mr. Elam has served as a member of Savara’s Board of Directors since February 2009. Since February 2013, Mr. Elam has served as a member of the Board of Directors as well as the President and Chief Executive Officer of Rezolute, Inc., a biopharmaceutical company focused on developing therapies for metabolic diseases with serious unmet needs. Prior to his tenure at Rezolute, Mr. Elam served as a senior executive in the pharmaceutical industry including as Senior Vice President and Head of the Pulmonary Business Unit of Nektar Therapeutics as well as President and Chief Executive Officer of a European medical device company. Earlier in his career, he was a Co-Founder and the Chief Financial Officer of E2open, Inc. as well as a Partner in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Elam holds a J.D. from Harvard Law School and a B.A. from Howard University.
Mr. Hawkins has served as a member of Savara’s Board of Directors since October 2010. Mr. Hawkins is currently the President, Chief Executive Officer and Chair of the Board of Directors of Lumos Pharma, Inc., a clinical stage biotechnology company focused on bringing novel therapies to patients with severe, rare, and genetic diseases, whose medical needs are unmet. In addition, Mr. Hawkins currently serves on the Board of Directors of several privately held life sciences companies, as well as Plus Therapeutics Inc. (formerly Cytori Therapeutics, Inc.), and previously served on the Board of Directors of SciClone Pharmaceuticals, Inc. Prior to his tenure with Lumos Pharma, Inc., which began in September 2010, Mr. Hawkins, founded and advised numerous pharmaceutical companies including Sensus, where he served as Co-Founder and Chair of the Board of Directors until it was sold to Pfizer. From 1981 to 2000, Mr. Hawkins was Founder, President and Chief Executive Officer of Pharmaco where he guided the company’s growth to more than 2,000 employees. The company later merged with PPD to form PPD Pharmaco, one of the largest clinical contract research organizations in the world. Mr. Hawkins holds his B.S. in Biology from Ohio University.
Dr. McCracken has served as Savara’s Lead Independent Director since December 2019 and a member of the company’s Board of Directors since October 2013. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. Dr. McCracken also serves on the Board of Directors of Lumos Pharma, Inc. and Modalis Therapeutics Corporation, as well as the Board of Directors of the privately held companies Regimmune Inc. and Neuropore Therapies, Inc. From July 2011 to September 2013, Dr. McCracken was Vice President and Global Head of Business Development & Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to that he served as General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Before joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a B.S. in Microbiology, a M.S. in Pharmacology and a D.V.M from The Ohio State University.
Mr. Ramsay has served as a member of Savara’s Board of Directors since April 2017 and as a member of the Board of Directors of Mast Therapeutics, Inc. from June 2011 to April 2017. Mr. Ramsay currently provides consulting services to publicly traded and privately-held biotechnology companies. Mr. Ramsay serves on the Board of Directors of La Jolla Pharmaceutical Company, as well as the Board of Directors of Exuma Biotech, Inc., a privately held biotechnology company. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc., a private, clinical stage biotechnology company focused on the development and commercialization of neurotoxin products for therapeutic and aesthetic applications. Mr. Ramsay served as Chief Financial Officer of Halozyme Therapeutics, Inc., a biotechnology company developing and commercializing novel oncology therapies, from May 2013 until his retirement in July 2015 and from 2003 to 2009. He also served as Halozyme’s Vice President, Corporate Development. Prior to Halozyme, Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry and as Vice President, Treasurer and Director, Corporate Finance with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), a multinational specialty pharmaceutical company. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay holds a B.S. in Business Administration from the University of California, Berkeley and a M.B.A. with a dual major in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.
Dr. Sun has served as a member of Savara’s Board of Directors since December 2019. Dr. Sun joined Bain Capital Life Sciences, LP. in August 2016 and has served as a Managing Director since January 2021. Dr. Sun also serves on the Board of Directors of Arcutis Biotherapeutics and Annexon Biosciences. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock’s Alpha Strategies Group and Senior Analyst for BlackRock’s Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a Senior Healthcare Analyst at Citadel and Alyeska Investment Group in Chicago and worked as a Pharmaceuticals Equity Research Analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a Senior Scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun holds a Ph.D. degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in chemistry.
Dr. An van Es-Johansson has served on Savara’s Board of Directors since December 2019. Most recently, she was the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease. From May 2005 to September 2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR Medical Affairs for Specialty Care and Partner Products from March 2013 to January 2018. Prior to her time at Sobi, Dr. van Es-Johansson served in leadership positions at large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum. From 2004 to 2016 she was a member of the Scientific Advisory Board for Uppsala Bio and currently serves on the Board of Directors at Medivir AB, Plus Therapeutics, Inc., Lumos Pharma, Inc., and the privately held company Agendia BV. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.
Back to Top
Savara Nasdaq Opening Bell Ceremony - July 23, 2018
×

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site.

We track anonymized user information to improve our website.
  • _ga
  • _gid
  • _gat

Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return. With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
  • __utma
  • __utmt
  • __utmb
  • __utmz
  • __utmv

Decline all Services
Accept all Services